These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 14610412)

  • 1. Management of bone loss in men with prostate cancer.
    Higano CS
    J Urol; 2003 Dec; 170(6 Pt 2):S59-63; discussion S64. PubMed ID: 14610412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.
    Conde FA; Sarna L; Oka RK; Vredevoe DL; Rettig MB; Aronson WJ
    Urology; 2004 Aug; 64(2):335-40. PubMed ID: 15302490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.
    Wadhwa VK; Weston R; Mistry R; Parr NJ
    BJU Int; 2009 Sep; 104(6):800-5. PubMed ID: 19338564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies.
    Diamond TH; Higano CS; Smith MR; Guise TA; Singer FR
    Cancer; 2004 Mar; 100(5):892-9. PubMed ID: 14983482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapy.
    Bruder JM; Ma JZ; Basler JW; Welch MD
    Urology; 2006 Jan; 67(1):152-5. PubMed ID: 16413352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer.
    Kiratli BJ; Srinivas S; Perkash I; Terris MK
    Urology; 2001 Jan; 57(1):127-32. PubMed ID: 11164157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteoporosis due to androgen deprivation therapy in men with prostate cancer.
    Daniell HW
    Urology; 2001 Aug; 58(2 Suppl 1):101-7. PubMed ID: 11502461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
    Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
    Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of decreased bone mineral density in men starting androgen-deprivation therapy for prostate cancer.
    Panju AH; Breunis H; Cheung AM; Leach M; Fleshner N; Warde P; Duff-Canning S; Krahn M; Naglie G; Tannock I; Tomlinson G; Alibhai SM
    BJU Int; 2009 Mar; 103(6):753-7. PubMed ID: 19007370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of zoledronic acid in men receiving androgen deprivation therapy for prostate cancer with severe osteopenia or osteoporosis.
    Campbell SC; Bhoopalam N; Moritz TE; Pandya M; Iyer P; Vanveldhuizen P; Ellis NK; Thottapurathu L; Garewal H; Warren SR; Friedman N; Reda DJ
    Urology; 2010 May; 75(5):1138-43. PubMed ID: 20303574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy.
    Grossmann M; Hamilton EJ; Gilfillan C; Bolton D; Joon DL; Zajac JD
    Med J Aust; 2011 Mar; 194(6):301-6. PubMed ID: 21426285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naive prostate carcinoma.
    Satoh T; Kimura M; Matsumoto K; Tabata K; Okusa H; Bessho H; Iwamura M; Ishiyama H; Hayakawa K; Baba S
    Cancer; 2009 Aug; 115(15):3468-74. PubMed ID: 19484786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for bone loss with prostate cancer in Korean men not receiving androgen deprivation therapy.
    Kim SO; Kang TW; Kwon D; Park K; Ryu SB
    Int Braz J Urol; 2009; 35(2):183-8; discussion 189. PubMed ID: 19409122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis.
    Planas J; Trilla E; Raventós C; Cecchini L; Orsola A; Salvador C; Placer J; Encabo G; Morote J
    BJU Int; 2009 Dec; 104(11):1637-40. PubMed ID: 19549260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer.
    Greenspan SL; Coates P; Sereika SM; Nelson JB; Trump DL; Resnick NM
    J Clin Endocrinol Metab; 2005 Dec; 90(12):6410-7. PubMed ID: 16189261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician.
    Higano CS
    Urol Clin North Am; 2004 May; 31(2):331-52. PubMed ID: 15123412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationship between daily calcium intake and bone mineral density in men with prostate cancer.
    Planas J; Morote J; Orsola A; Salvador C; Trilla E; Cecchini L; Raventós CX
    BJU Int; 2007 Apr; 99(4):812-5; discussion 815-6. PubMed ID: 17378843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen deprivation therapy for prostate cancer results in significant loss of bone density.
    Wei JT; Gross M; Jaffe CA; Gravlin K; Lahaie M; Faerber GJ; Cooney KA
    Urology; 1999 Oct; 54(4):607-11. PubMed ID: 10510915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Influence of androgen deprivation therapy on bone mineral density in men with prostate cancer].
    Deng J; Li W; Yang L; Wang L; Zou D
    Zhonghua Nan Ke Xue; 2004 Oct; 10(10):761-3. PubMed ID: 15562791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteoporosis and prostate cancer: a cross-sectional study of Danish men with prostate cancer before androgen deprivation therapy.
    Poulsen MH; Frost M; Abrahamsen B; Brixen K; Walter S
    Scand J Urol; 2014 Aug; 48(4):350-5. PubMed ID: 24548220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.